Last updated on July 2019
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
Brief description of study
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.
Clinical Study Identifier: NCT02099591
